Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Vertex Pharmaceuticals Incorporated To Contact the Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) (NasdaqGS: VRTX).

The investigation focuses on whether the Company and its executives violated federal securities laws by misrepresenting the results of its Phase 2 study of its experimental drugs VX-909 and Kalydeco in statements made on May 7, 2012 and May 29, 2012. On June 27, 2012 the Company admitted that those prior statements regarding the Phase 2 study were inaccurate and Vertex's stock price declined significantly on the news.

Take Action

If you purchased Vertex stock or options between May 7, 2012 and June 27, 2012 and would like to discuss your legal rights, contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Vertex’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.